10 newer rulings cite the same tariff codes.
Classification can shift over time. Review the more recent rulings below before relying on this one.
The tariff classification of MBX-102 tablets from Canada
Issued July 2, 2002 by U.S. Customs and Border Protection.
Cite this ruling
Copies to clipboardI8 I81539 (July 2, 2002)
Tariff classification
HTS codes: 3004.90.9190
Headings: 3004
Product description
The subject product, MBX-102 tablets, is a medicament containing the active ingredient (-)-Halofenate (CAS-24136-23-0), an antihyperlipoproteinemic agent and uricosuric agent.
CBP rationale
the applicable subheading for the subject tablets will be 3004.90.9190, Harmonized Tariff Schedule of the United States (HTS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses or in forms or packings for retail sale: Other: Other: Other.
Full text
NY I81539 July 2, 2002 CLA-2-30:RR:NC:2:238 I81539 CATEGORY: Classification TARIFF NO.: 3004.90.9190 Mr. James F. Morgan PBB Global Logistics 883-D Airport Park Road Glen Burnie, MD 21061 RE: The tariff classification of MBX-102 tablets from Canada Dear Mr. Morgan. : In your letter dated April 29, 2002, on behalf of your client, Pateon Inc., you requested a tariff classification ruling. The subject product, MBX-102 tablets, is a medicament containing the active ingredient (-)-Halofenate (CAS-24136-23-0), an antihyperlipoproteinemic agent and uricosuric agent. You state in your letter that the tablets will be imported for use in FDA-regulated Phase I clinical trials in order to evaluate the efficacy of (-)-Halofenate for the treatment of non-insulin-dependent Type II diabetes, and for lowering lipid levels. Pursuant to the General Notice entitled Guidance in the Tariff Classification of Pharmaceutical Products Imported for Clinical Research (see Customs Bulletin and Decisions, Vol. 34, No. 21, May 24, 2000), the applicable subheading for the subject tablets will be 3004.90.9190, Harmonized Tariff Schedule of the United States (HTS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses or in forms or packings for retail sale: Other: Other: Other.” The rate of duty will be free. This merchandise may be subject to the requirements of the Federal Food, Drug, and Cosmetic Act, which is administered by the U.S. Food and Drug Administration. You may contact them at 5600 Fishers Lane, Rockville, Maryland 20857, telephone number 301-443-1544. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at 646-733-3033. Sincerely, Robert B. Swierupski Director, National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification of Metformin Hydrochloride Extended Release Tablets in dosage form, from India
The tariff classification of Sodium Phenylacetate and Sodium Benzoate injection vials in dosage form, from India
The tariff classification, country of origin and country of origin marking of the AUGMENT® Bone Graft Kit from the United Kingdom and the applicability of subheading 9801.00.10, HTSUS
The tariff classification of GRASTEK® and RAGWITEK® sublingual tablets in dosage form, from Denmark
The tariff classification of Glyburide Tablets and Glyburide-Metformin Hydrochloride Tablets in dosage form, from India
The tariff classification of Voriconazole Tablets and Nateglinide Tablets in dosage form, from Malta and India, respectively
The tariff classification of Zolderonic Acid Injection in dosage form, from India
The tariff classification of Zoledronic Acid Injections in dosage form, from Austria
The tariff classification, country of origin marking of KANUMA™ (sebelipase alfa) in dosage form and the applicability of subheading 9801.00.10, HTSUS
The tariff classification of Etomidate Injection, USP and Glipizide Extended Release Tablets, in dosage form, from India
Follow I81539
Get an email if this ruling is revoked or modified, or a newer ruling supersedes it.
One email per day at most. Confirm your address once, unsubscribe anytime.
Searching CBP rulings the smart way
Rulings are precedent. See which ones apply to your product: TariffLens semantically searches all 200,000+ CBP rulings and builds defensible classifications backed by ruling citations.